Title : Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Pub. Date : 2022 May 26

PMID : 35619325






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell product, lisocabtagene maraleucel (liso-cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. lisocabtagene maraleucel CD19 molecule Homo sapiens